Comparative studies of guanfacine and methyldopa

Area of Science:

• Cardiology
• Pharmacology
• Internal Medicine

Background:

• Hypertension remains a significant global health concern, necessitating effective therapeutic agents.
• Central sympathetic inhibitors play a crucial role in managing blood pressure.
• Methyldopa is a commonly used antihypertensive, but its efficacy and side effect profile warrant comparison with newer agents.

Purpose of the Study:

• To compare the antihypertensive efficacy and tolerability of guanfacine with methyldopa.
• To evaluate the effectiveness of guanfacine in patients with essential or renal hypertension (WHO grade I-II).

Main Methods:

• A randomized cross-over study involving 20 out-patients with hypertension.
• Patients received either guanfacine (3.5 mg daily) or methyldopa (1.2 g daily) for 6 weeks.
• Blood pressure was monitored to assess mean arterial pressure (MAP) reduction and normalization.

Main Results:

• Guanfacine resulted in a 24% decrease in MAP, with 50% achieving normalized blood pressure (BP < 145/95 mm Hg).
• Methyldopa achieved a 12% decrease in MAP, with only 15% achieving normalized blood pressure.
• Guanfacine showed a higher 'good control' rate (90%) compared to methyldopa (45%), with fewer treatment failures due to intolerance or ineffectiveness.

Conclusions:

• Guanfacine is a potent antihypertensive agent, demonstrating greater efficacy than methyldopa at the doses studied.
• Guanfacine offers a promising alternative for hypertension management, though potential side effects like dry mouth and sedation should be monitored.
• Further research is warranted to explore the long-term efficacy and safety of guanfacine in diverse hypertensive populations.